Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)
- PMID: 29525777
- DOI: 10.1136/annrheumdis-2017-212565
Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)
Abstract
A European League Against Rheumatism-American College of Rheumatology working group consisting of practising and academic rheumatologists, a rheumatology researcher and a patient representative created a succinct general statement describing rheumatic and musculoskeletal diseases (RMDs) in adults and children in language that can be used in conversations with the lay public, media, healthcare providers and other stakeholders. Based on the literature review, several elements were deemed important for inclusion in the description of RMDs. First, RMDs encompass many different diseases that can affect individuals at any age, including children. Second, there are various pathophysiological pathways underlying different RMDs. Third, the impact of RMDs on individuals and society should be emphasised. The working group agreed that the language should be comprehensible to the lay public. Thus, the following description of RMDs has been developed: 'Rheumatic and musculoskeletal diseases (RMDs) are a diverse group of diseases that commonly affect the joints, but can affect any organ of the body. There are more than 200 different RMDs, affecting both children and adults. They are usually caused by problems of the immune system, inflammation, infections or gradual deterioration of joints, muscles and bones. Many of these diseases are long term and worsen over time. They are typically painful and limit function. In severe cases, RMDs can result in significant disability, having a major impact on both quality of life and life expectancy.' This description can be used by rheumatology groups, researchers and those who work in advocacy and education related to RMDs.
Keywords: epidemiology; health services research; qualitative research.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).Arthritis Rheumatol. 2018 Jun;70(6):826-831. doi: 10.1002/art.40448. Epub 2018 Mar 13. Arthritis Rheumatol. 2018. PMID: 29532625
-
The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases.Clin Rheumatol. 2015 May;34(5):819-29. doi: 10.1007/s10067-014-2841-6. Epub 2014 Dec 14. Clin Rheumatol. 2015. PMID: 25501633 Free PMC article. Review.
-
EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs).Ann Rheum Dis. 2021 Jul;80(7):840-847. doi: 10.1136/annrheumdis-2020-219816. Epub 2021 Jan 22. Ann Rheum Dis. 2021. PMID: 33483318
-
2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.Ann Rheum Dis. 2023 Jan;82(1):48-56. doi: 10.1136/annrheumdis-2021-222020. Epub 2022 Mar 8. Ann Rheum Dis. 2023. PMID: 35260387 Review.
-
The population impact of rheumatic and musculoskeletal diseases in relation to other non-communicable disorders: comparing two estimation approaches.Rheumatol Int. 2018 May;38(5):905-915. doi: 10.1007/s00296-018-3990-8. Epub 2018 Feb 8. Rheumatol Int. 2018. PMID: 29423535
Cited by
-
Impact of COVID-19 Pandemic on Patients with Rheumatic and Musculoskeletal Diseases: Disruptions in Care and Self-Reported Outcomes.J Patient Exp. 2022 May 23;9:23743735221102678. doi: 10.1177/23743735221102678. eCollection 2022. J Patient Exp. 2022. PMID: 35647269 Free PMC article.
-
Treatment of Fissure Caries of Children with Severe Rheumatic Diseases with Difficulty in Opening the Mouth.Contemp Clin Dent. 2022 Jul-Sep;13(3):274-279. doi: 10.4103/ccd.ccd_172_20. Epub 2022 Sep 24. Contemp Clin Dent. 2022. PMID: 36213848 Free PMC article.
-
Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases.Int J Mol Sci. 2021 May 20;22(10):5387. doi: 10.3390/ijms22105387. Int J Mol Sci. 2021. PMID: 34065409 Free PMC article. Review.
-
Direct and Indirect Relationships Between Physical Activity, Fitness Level, Kinesiophobia, and Health-Related Quality of Life in Patients with Rheumatic and Musculoskeletal Diseases: A Network Analysis.J Pain Res. 2021 Oct 28;14:3387-3399. doi: 10.2147/JPR.S323424. eCollection 2021. J Pain Res. 2021. PMID: 34737633 Free PMC article.
-
[Criteria for the authorization of training in medical specialist competence in internal medicine and rheumatology-A position paper of the German Society for Rheumatology and Clinical Immunology].Z Rheumatol. 2025 Feb;84(1):59-67. doi: 10.1007/s00393-024-01598-5. Epub 2024 Dec 12. Z Rheumatol. 2025. PMID: 39666002 Free PMC article. German.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources